The study is examining if lowering Lipoprotein (a), a type of cholesterol, can reduce the risk of cardiovascular events. If you have known cardiovascular disease or are at risk of cardiovascular disease (including a family history), you might be eligible for this 4-year study.
This study is being conducted at our at our Western Sydney, Central Coast, Canberra, and Brisbane sites.
Apply Now
Phase 3 placebo-control study assessing the efficacy and safety of Plozasiran on the reduction of triglyceride levels in adults with mild-moderate hypertriglyceridemia. If you have hypertriglyceridemia and are currently prescribed a lipid-lowering medication, you might be eligible for this 15-month study.
This study is being conducted at our Western Sydney site only.
Apply Now
Phase 3 placebo-control study assessing the efficacy and safety of Plozasiran on the reduction of triglyceride levels in adults with severe hypertriglyceridemia. If you have hypertriglyceridemia and are currently prescribed a lipid-lowering medication, you might be eligible for this 58-week study.
This study is being conducted at our Western Sydney site only.
Apply Now
A Phase 2 Clinical Trial Evaluating the Effectiveness of Alnylam’s potential New Add-On Treatment Zilebesiran versus Placebo on Blood Pressure Control in Adults with High Cardiovascular Risk that are currently taking two or more Anti-Hypertensive Treatments.
This study is being conducted at our Western Sydney, Central Coast and Canberra sites.
Apply Now
A phase 3 study evaluating the impact of the investigational treatment CagriSema* on cardiovascular events in individuals with established cardiovascular disease and Type 2 diabetes.
This study is being conducted at our Central Coast site.
Apply Now
Research study investigating a new cholesterol medication on reducing cardiovascular events in individuals living with, or at risk of cardiovascular disease.
This study is being conducted at our Canberra site.
Apply Now
